The polarization of immune cells in the tumour environment by TGFÎ 2

Nature Reviews Immunology

Volumn 10, Issue 8, 2010, Pages 554-567

  Flavell, Richard A ^a   Sanjabi, Shomyseh ^a,b,c   Wrzesinski, Stephen H ^a,d   Licona Limón, Paula ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Veteran's Administration Connecticut Healthcare Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; CYTOKINE;

CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POLARITY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; NATURAL KILLER CELL; NEUTROPHIL COUNT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EXTRAMEDULLARY HEMATOPOIESIS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; METABOLISM; NEOPLASMS; NEUTROPHIL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL POLARITY; CYTOKINES; DENDRITIC CELLS; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; IMMUNOSUPPRESSION; KILLER CELLS, NATURAL; MACROPHAGES; NEOPLASMS; NEUTROPHILS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 77954951446     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2808     Document Type: Review

References (161)

1. Massague, J. TGFβ in cancer. Cell 134, 215-230 (2008).
2. Wrzesinski, S. H., Wan, Y. Y. & Flavell, R. A. Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13, 5262-5270 (2007).
3. Padua, D. & Massague, J. Roles of TGFβ in metastasis. Cell Res. 19, 89-102 (2009).
4. Tian, M. & Schiemann, W. P. The TGF-β paradox in human cancer: an update. Future Oncol. 5, 259-271 (2009).
5. Bierie, B. & Moses, H. L. Transforming growth factor β (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev. 21, 49-59 (2010).
6. Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K. & Flavell, R. A. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
7. H17 cells in tumour immunity and immunotherapy. Nature Rev. Immunol. 10, 248-256 (2010).
8. Yang, Q., Goding, S. R., Hokland, M. E. & Basse, P. H. Antitumor activity of NK cells. Immunol. Res. 36, 13-25 (2006).
9. Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nature Immunol. 6, 600-607 (2005).
10. Rook, A. H. et al. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136, 3916-3920 (1986).
11. Wahl, S. M., Wen, J. & Moutsopoulos, N. M. The kiss of death: interrupted by NK-cell close encounters of another kind. Trends Immunol. 27, 161-164 (2006).
12. Trotta, R. et al. TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 181, 3784-3792 (2008).
13. Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nature Immunol. 9, 495-502 (2008).
14. Castriconi, R. et al. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl Acad. Sci. USA 100, 4120-4125 (2003).
15. + T cells in glioma patients. Neuro. Oncol. 12, 7-13 (2010).
16. Lee, J.-C., Lee, K.-M., Kim, D.-W. & Heo, D. S. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172, 7335-7340 (2004).
17. Kopp, H. G., Placke, T. & Salih, H. R. Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69, 7775-7783 (2009).
18. Li, H., Han, Y., Guo, Q., Zhang, M. & Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J. Immunol. 182, 240-249 (2009).
19. Steinman, R. M. & Banchereau, J. Taking dendritic cells into medicine. Nature 449, 419-426 (2007).
20. Ferlazzo, G. & Munz, C. Dendritic cell interactions with NK cells from different tissues. J. Clin. Immunol. 29, 265-273 (2009).
21. Dhodapkar, M. V., Dhodapkar, K. M. & Palucka, A. K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 15, 39-50 (2008).
22. Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
23. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001).
24. Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
25. + regulatory T cells. J. Dermatol. Sci. 54, 69-75 (2009).
26. Kortylewski, M. et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114-123 (2009).
27. Ito, M. et al. Tumor-derived TGFβ-1 induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 176, 5637-5643 (2006).
28. Weber, F. et al. Transforming growth factor-p 1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunol. Immunother. 54, 898-906 (2005).
29. Halliday, G. M. & Le, S. Transforming growth factor-p produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int. Immunol. 13, 1147-1154 (2001).
30. Bekeredjian-Ding, I. et al. Tumour-derived prostaglandin E and transforming growth factor-p synergize to inhibit plasmacytoid dendritic cell-derived interferon-a. Immunology 128, 439-450 (2009).
31. + T regulatory 1 cells to suppress antitumor immunity. J. Immunol. 175, 2931-2937 (2005).
32. Roncarolo, M. G., Levings, M. K. & Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5-F9 (2001).
33. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235-247 (2003).
34. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199, 1467-1477 (2004).
35. high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108, 2655-2661 (2006).
36. Chung, D. J. et al. Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114, 555-563 (2009).
37. + regulatory T cells. Proc. Natl Acad. Sci. USA 104, 282 1-2826 (2007).
38. Levings, M. K., Bacchetta, R., Schulz, U. & Roncarolo, M. G. The role of IL-10 and TGF-p in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 129, 263-276 (2002).
39. + regulatory T cell proliferation. J. Exp. Med. 202, 919-929 (2005).
40. + T regulatory cells: role of tumor-derived TGF-p. J. Immunol. 178, 2883-2892 (2007).
41. + regulatory T cells. J. Immunol. 181, 6923-6933 (2008).
42. + regulatory T cells. J. Immunol. 182, 2795-2807 (2009).
43. Mantovani, A., Sica, A., Allavena, P., Garlanda, C. & Locati, M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70, 325-330 (2009).
44. Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's Lymphoma. N. Engl. J. Med. 362, 875-885 (2010).
45. Martinez, F O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483 (2009).
46. Sica, A. et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349-355 (2008).
47. Byrne, S. N., Knox, M. C. & Halliday, G. M. TGFp is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol. Cell Biol. 86, 92-97 (2008).
48. Biswas, S. K. et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-KB and enhanced IRF-3/STAT1 activation). Blood 107, 2112-2122 (2006).
49. Saccani, A. et al. p50 nuclear factor-icB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66, 11432-11440 (2006).
50. Porta, C. et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor KB. Proc. Natl Acad. Sci. USA 106, 14978-14983 (2009).
51. Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237 (2010).
52. Torroella-Kouri, M. et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 69, 4800-4809 (2009).
53. Umemura, N. et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J. Leukoc. Biol. 83, 1136-1144 (2008).
54. Fichtner-Feigl, S., Strober, W, Kawakami, K., Puri, R. K. & Kitani, A. IL-13 signaling through the IL-13a2 receptor is involved in induction of TGF-p1 production and fibrosis. Nature Med. 12, 99-106 (2006).
55. Gratchev, A. et al. Activation of a TGF-p-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-p receptor II. J. Immunol. 180, 6553-6565 (2008).
56. Allen, S. S. et al. Altered inflammatory responses following transforming growth factor-p neutralization in experimental guinea pig tuberculous pleurisy. Tuberculosis (Edinb.) 88, 430-436 (2008).
57. Smith, W. B. et al. Transforming growth factor-p 1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J. Immunol. 157, 360-368 (1996).
58. Shen, L. et al. Inhibition of human neutrophil degranulation by transforming growth factor-p 1. Clin. Exp. Immunol. 149, 155-161 (2007).
59. Di Carlo, E. et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339-345 (2001).
60. Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-p: "N1" versus "N2" TAN. Cancer Cell 16, 183-194 (2009).
61. Nozawa, H., Chiu, C. & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493-12498 (2006).
62. Pekarek, L. A., Starr, B. A., Toledano, A. Y & Schreiber, H. Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181, 435-440 (1995).
63. Tazawa, H. et al. Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am. J. Pathol. 163, 2221-2232 (2003).
64. Colombo, M. P., Modesti, A., Parmiani, G. & Forni, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52, 4853-4857 (1992).
65. Hicks, A. M. et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc. Natl Acad. Sci. USA 103, 7753-7758 (2006).
66. Stoppacciaro, A. et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon y. J. Exp. Med. 178, 151-161 (1993).
67. + T cell infiltrations within esophageal carcinomas. Cancer Res. 61, 3932-3936 (2001).
68. + T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132-5136 (2001).
69. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
70. Gao, Q. et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25, 2586-2593 (2007).
71. Thomas, D. A. & Massague, J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380 (2005).
72. + T cells activates the antitumor immune response cycle. Mol. Cancer Ther. 5, 1733-1743 (2006).
73. Franciszkiewicz, K. et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res. 69, 6249-6255 (2009).
74. Gorelik, L. & Flavell, R. A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171-181 (2000).
75. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118-1122 (2001).
76. + T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65, 1761-1769 (2005).
77. + T cells. Clin. Cancer Res. 16, 164-173 (2010).
78. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515-520 (2000).
79. Terabe, M. et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198, 1741-1752 (2003).
80. Nam, J. S. et al. An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835-3843 (2008).
81. Wallace, A. et al. Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966-3974 (2008).
82. + T cells. Int. J. Cancer 126, 1666-1674 (2010).
83. + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody. Clin. Cancer Res. 15, 6560-6569 (2009).
84. Ueda, R. et al. Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin. Cancer Res. 15, 6551-6559 (2009).
85. + T cells. Immunity 31, 131-144 (2009).
86. Ahmadzadeh, M. & Rosenberg, S. A. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. 174, 5215-5223 (2005).
87. + T cells through effects on TCR signaling and Spred1 expression. Cancer Immunol. Immunother. 58, 1809-1818 (2009).
88. Nam, J. S. et al. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68, 3915-3923 (2008).
89. + T cells display enhanced antitumor immunity. Blood 11 4, 596-599 (2009).
90. Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 11 2, 362-373 (2008).
91. Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787-798 (2009).
92. Li, M. O. & Flavell, R. A. TGF-β: a master of all T cell trades. Cell 134, 392-404 (2008).
93. + T cell function. Jpn. J. Cancer Res. 84, 315-325 (1993).
94. Maeda, H. & Shiraishi, A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156, 73-78 (1996).
95. Knutson, K. L. & Disis, M. L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54, 721-728 (2005).
96. + T cells. Curr. Opin. Immunol. 21, 200-208 (2009).
97. + T cell to a fully functional tumor killer cell. Cancer Res. 62, 6438-6441 (2002).
98. Perez-Diez, A. et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346-5354 (2007).
99. Martin-Orozco, N. & Dong, C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr. Opin. Invest. Drugs 10, 543-549 (2009).
100. Murugaiyan, G. & Saha, B. Protumor vs antitumor functions of IL-17. J. Immunol. 183, 4169-4175 (2009).
101. + IL-17-producing T cells in ovarian cancer. Proc. Natl Acad. Sci. USA 105, 15505-15510 (2008).
102. Su, X. et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184, 1630-1641 (2010).
103. Nurieva, R., Yang, X. O., Chung, Y. & Dong, C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J. Immunol. 182, 2565-2568 (2009).
104. + T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651-667 (2010).
105. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637-650 (2010).
106. Kryczek, I. et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178, 6730-6733 (2007).
107. Pellegrini, M. et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nature Med. 15, 528-536 (2009).
108. + regulatory T cells: more of the same or a division of labor? Immunity 30, 626-635 (2009).
109. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004).
110. Merlo, A. et al. FOXP3 expression and overall survival in breast cancer. J. Clin. Oncol. 27, 1746-1752 (2009).
111. + regulatory T cells in a murine model of pancreas cancer. J. Immunother. 32, 12-21 (2009).
112. Beyer, M. & Schultze, J. L. Regulatory T cells in cancer. Blood 108, 804-811 (2006).
113. Solinas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86, 1065-1073 (2009).
114. - T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1. J. Immunol. 182, 111-120 (2009).
115. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
116. - T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172, 5149-5153 (2004).
117. Petrausch, U. et al. Disruption of TGF-β signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J. Immunol. 183, 3682-3689 (2009).
118. + T regulatory cells. Curr. Opin. Immunol. 20, 327-331 (2008).
119. + suppressor T cells resurrected. Hum. Immunol. 69, 715-720 (2008).
120. + regulatory T cells. J. Immunol. 177, 896-904 (2006).
121. + T cells infiltrating prostatic tumors are induced to become suppressor cells. J. Immunol. 183, 4848-4852 (2009).
122. + suppressive T cells in colorectal cancer tissue. Gut 58, 520-529 (2009).
123. + regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13, 6947-6958 (2007).
124. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. & Kaer, L. V. NKT cells: what's in a name? Nature Rev. Immunol. 4, 231-237 (2004).
125. Berzofsky, J. & Terabe, M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol. Immunother. 57, 1679-1683 (2008).
126. Berzofsky, J. A. & Terabe, M. The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med. 9, 667-672 (2009).
127. van der Vliet, H. J. et al. Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J. Immunol. 180, 7287-7293 (2008).
128. Calvo-Aller, E. et al. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-β receptor I kinase. ASCO Annual Meeting. J. Clin. Oncol. Abstr. 26, 14554 (2008).
129. Fakhrai, H. et al. Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 13, 1052-1060 (2006).
130. Nemunaitis, J. et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721-4730 (2006).
131. Nemunaitis, J. et al. Phase II trial of belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 16, 620-624 (2009).
132. Schlingensiepen, K.-H. et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129-139 (2006).
133. Schlingensiepen, R. et al. Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15, 94-104 (2005).
134. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M. & Chen, L. Immunostimulatory monoclonal antibodies for cancer therapy. Nature Rev. Cancer 7, 95-106 (2007).
135. H-17 cells does require TGF-β! Nature Immunol. 9, 588-590 (2008).
136. Schreiber, T. H., Deyev, V. V., Rosenblatt, J. D. & Podack, E. R. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 69, 2026-2033 (2009).
137. Levy, L. & Hill, C. S. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41-58 (2006).
138. Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature Rev. Cancer 3, 807-821 (2003).
139. Nagaraj, N. S. & Datta, P. K. Targeting the transforming growth factor-β signaling pathway in human cancer. Expert Opin. Investig. Drugs 19, 77-91 (2010).
140. Wei, S. et al. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor β. Cancer Res. 68, 5432-5438 (2008).
141. Schlingensiepen, K.-H. et al. The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. J. Clin. Immunol. 22, 3132 (2004).
142. Khaw, P. et al. A phase III study of subconjunctival human anti-transforming growth factor β(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 11 4, 1822-1830 (2007).
143. Benigni, A. et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14, 1816-1824 (2003).
144. Morris, J. C. et al. Phase I/II study of GC1008: A human anti-transforming growth factor-β (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). ASCO Annual Meeting. J. Clin. Oncol. Abstr. 26, 9028 (2008).
145. Nam, J.-S. et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res. 66, 6327-6335 (2006).
146. Zhong, Z. et al. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191-1205 (2010).
147. Kano, M. R. et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl Acad. Sci. USA 104, 3460-3465 (2007).
148. Scott Sawyer, J. et al. Synthesis and activity of new aryl-and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorg. Med. Chem. Lett. 14, 3581-3584 (2004).
149. Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74 (2002).
150. Saunier, E. F. & Akhurst, R. J. TGFβ inhibition for cancer therapy. Curr. Cancer Drug Targets. 6, 565-578 (2006).
151. Hayashi, T. et al. Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 10, 7540-7546 (2004).
152. Uhl, M. et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961 (2004).
153. Ehata, S. et al. Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 98, 127-133 (2007).
154. Kim, S. et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res. 68, 10247-10256 (2008).
155. Suzuki, E. et al. A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 67, 2351-2359 (2007).
156. Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene 24, 3864-3874 (2005).
157. Llopiz, D. et al. Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy. Int. J. Cancer 125, 2614-2623 (2009).
158. Yang, Y.-A. et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615 (2002).
159. Fujita, T. et al. Inhibition of transforming growth factor-β- mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 69, 5142-5150 (2009).
160. Foster, A. E. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J. Immunother. 31, 500-505 (2008).
161. Melisi, D. et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer. Ther. 7, 829-840 (2008).